Imatinib-induced purpuric vasculitis;Vasculite purpurique induite par l'imatinib

Annales de Dermatologie et de Venereologie

Volumn 130, Issue 8-9 I, 2003, Pages 765-767

  Hamm, M ^a   Touraud, J P ^a   Mannone, L ^b   Klisnick, J ^a   Ponnelle, T ^c   Lambert, D ^a  

^a HÔPITAL DU BOCAGE   (France)

^b Medical University of Dijon   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HYDROXYUREA; IMATINIB; PIPOBROMAN; PROTEIN TYROSINE KINASE INHIBITOR;

AGED; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG EFFECT; DRUG RESPONSE; HISTOLOGY; HUMAN; MALE; PHILADELPHIA 1 CHROMOSOME; PURPURIC VASCULITIS; RASH; SKIN BIOPSY; SKIN TOXICITY; SYMPTOM; VASCULITIS;

AGED; ENZYME INHIBITORS; HUMANS; MALE; PIPERAZINES; PURPURA; PYRIMIDINES; VASCULITIS;

EID: 0142024096     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Brouard M, Saurat JH. Cutaneous reactions to STI 571. N Engl J Med 2001;345:618-9.
2. Valeyrie L, Bastuji-Garin S, Giraudier S, Bachot N, Wechsler J, Tulliez M et al. Toxidermies induites par le STI 571, inhibiteur spécifique de la tyrosine kinase de BCR-ABL dans le traitement des leucémies à chromosome philadelphie. Ann Dermatol Venereol 2001;128:3S69.
3. Brouard MC, Prins C, Mach-Pascual S, Saurat JH. Acute generalized exanthematous pustulosis associated with STI. 571 in a patient with chronic myeloid leukemia. Dermatology 2001;203:507-9.
4. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
5. Schindler T, Bornmann W, Pellicena P, Todd Miller W, Clarkson B, Kuriyan J. Structural mechanism of STI-571 inhibition of Abelson tyrosine kinase. Science 2000;289:1938-42.
6. Lyseng-Williamson K, Jarvis B. Imatinib. Drugs 2001;61:1765-74.
7. Druker BJ, Sawyers CL, Kantarjian H, Resta D, Reese S, Ford J et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2000;344:1038-42.
8. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Imatinib induces durable hematologic and cytogenetic responses in patients with accelereted phase chronic myeloid leukemia: results of a phase II study. Blood 2002;99:1928-37.
9. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
10. Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.